ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors

Abstract : The identification of unique cell-surface proteins expressed on tumor cells, yet not expressed on normal tissues, has been challenging for pediatric malignancies. The cell sur-face tyrosine kinase ALK (CD246, anaplastic lymphoma kinase) is a promising target for neuroblastoma in that it is expressed in either native, mutated, or over-expressed forms on the plasma membrane surface
Type de document :
Article dans une revue
Journal for Immunotherapy of Cancer, London : BioMed Central, 2013-, 2013, 1 (Suppl 1), pp.P27. 〈10.1186/2051-1426-1-S1-P27〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00881036
Contributeur : Ed. Bmc <>
Soumis le : jeudi 7 novembre 2013 - 13:14:47
Dernière modification le : vendredi 31 août 2018 - 08:46:10
Document(s) archivé(s) le : samedi 8 février 2014 - 07:15:08

Fichiers

Identifiants

Collections

UPMC | IFM

Citation

Rimas Orentas, Paola Lopomo, William Babbitt, Marc Vigny, Crystal Mackall. ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors. Journal for Immunotherapy of Cancer, London : BioMed Central, 2013-, 2013, 1 (Suppl 1), pp.P27. 〈10.1186/2051-1426-1-S1-P27〉. 〈inserm-00881036〉

Partager

Métriques

Consultations de la notice

271

Téléchargements de fichiers

120